
A new trifocal diffractive IOL (FineVision trifocal IOL, PhysIOL), implanted bilaterally, achieved a full range of adequate vision, satisfactory contrast sensitivity, and a lack of significant adverse photic phenomena, according to Spanish researchers reporting in BMC Ophthalmology.
